Tuesday, July 19, 2016
Diamyd Medical AB Says the company and University of California, Los Angeles (UCLA) advances therapeutic development for type 1 diabetes.
Says new preclinical study will evaluate if GABA in combination with both autoantigens improves efficacy even further.
Previously published results show that GABA in combination with either GAD65 or proinsulin result in strong synergistic effects on enhancing beta cell health and reversing hyperglycemia in preclinical type 1 diabetes mouse models.
Diamyd licenses exclusive rights from UCLA for therapeutic use of GABA alone or in combination with antigens for treatment of diabetes and other inflammation-related conditions.
Source : reuters.com
